MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, KRRO had -$9,457K decrease in cash & cash equivalents over the period. -$17,354K in free cash flow.

Cash Flow Overview

Change in Cash
-$9,457K
Free Cash flow
-$17,354K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-18,061 -49,157
Non-cash lease expense
178 326
Stock-based compensation expense
1,825 3,759
Depreciation expense
1,179 2,452
Net amortization of premiums and discounts on marketable securities
467 -
Loss on disposal of property and equipment
-81 -
Accounts receivable
-876 -
Prepaid expenses and other current assets
189 -
Accounts payable
-1,674 -
Accrued expenses and other current liabilities
-319 -
Deferred revenue
-1,268 -
Operating lease liabilities
-97 -
Other non-current assets
303 -
Net cash used in operating activities
-17,179 -43,680
Purchases of marketable securities
15,028 11,161
Proceeds from maturities of marketable securities
22,799 32,901
Purchases of property and equipment
175 259
Net cash provided by (used in) investing activities
7,596 21,481
Proceeds from pipe financing, net of issuance costs
0 0
Proceeds from exercises of stock options
128 177
Net cash provided by financing activities
128 177
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-2 -9
Net decrease in cash, cash equivalents and restricted cash
-9,457 -22,031
Cash and cash equivalents at beginning of period
59,049 -
Cash and cash equivalents at end of period
27,561 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Korro Bio, Inc. (KRRO)

Korro Bio, Inc. (KRRO)